David Lewis
Stock Analyst at Morgan Stanley
(2.72)
# 1,912
Out of 4,784 analysts
281
Total ratings
65.47%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $107 → $117 | $130.82 | -10.56% | 23 | Oct 17, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $258.75 | +15.94% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $227.50 | +20.88% | 23 | Oct 11, 2022 | |
| NVRO Nevro | Maintains: Equal-Weight | $55 → $54 | $5.84 | +824.66% | 12 | Aug 4, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $67.74 | +34.34% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $12.58 | +5,623.37% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $33.75 | +196.30% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $68.58 | -78.13% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $6.82 | +339.88% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $61.32 | +22.31% | 11 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $45 | $16.97 | +165.17% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $63.19 | -5.05% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $72.55 | +13.03% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $137.80 | +212.77% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $87.63 | +75.74% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $14.04 | +184.90% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $70.91 | +90.38% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $364.50 | -23.18% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $491.84 | -42.05% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $9.03 | +110.41% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $105.00 | -10.48% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $95.77 | -17.51% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $112.26 | +60.34% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $163.71 | +14.23% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $13.95 | +222.58% | 5 | Dec 15, 2020 |
Abbott Laboratories
Oct 17, 2024
Maintains: Equal-Weight
Price Target: $107 → $117
Current: $130.82
Upside: -10.56%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $258.75
Upside: +15.94%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $227.50
Upside: +20.88%
Nevro
Aug 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $54
Current: $5.84
Upside: +824.66%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $67.74
Upside: +34.34%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $12.58
Upside: +5,623.37%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $33.75
Upside: +196.30%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $68.58
Upside: -78.13%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $6.82
Upside: +339.88%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $61.32
Upside: +22.31%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $16.97
Upside: +165.17%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $63.19
Upside: -5.05%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $72.55
Upside: +13.03%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $137.80
Upside: +212.77%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $87.63
Upside: +75.74%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $14.04
Upside: +184.90%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $70.91
Upside: +90.38%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $364.50
Upside: -23.18%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $491.84
Upside: -42.05%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $9.03
Upside: +110.41%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $105.00
Upside: -10.48%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $95.77
Upside: -17.51%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $112.26
Upside: +60.34%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $163.71
Upside: +14.23%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $13.95
Upside: +222.58%